At the beginning of 2018, the biohybridization Laboratory, created as a result of a large competition between the Russian Federal government, began work at the Institute of Chemistry of St. Petersburg State University. The new unit is headed by One of the world's leading pharmacologists, Professor Arto Urtti (Finland).
The scientific goal of the project is to create a fundamental new biomaterial - biohybrid material - for use in many therapeutic and diagnostic areas of medicine, synthesizing molecular and supramolecular structures by combining living cells with the laboratory. The development of biological hybridization is achieved by solving problems at various levels of research:
Synthesis of new drugs, therapeutic peptides, hydrophilic polymers and luminescent markers (molecular level);
Create biocompatible polymer systems for encapsulation of drug and genetic constructs (supramolecular level),
Study methods of modification of living cells (cell level);
Develop systems to simulate the pharmacokinetics of polymer drug delivery systems and biohybridization (life systems modeling), testing developed systems using model animals (organisms).
Although the proposed system is relevant to a very wide range of biomedical applications, in this project the therapeutic system was developed to treat topical ocular diseases such as age-related macular degeneration, glaucoma and diabetic retinal diseases.